Journal
ACS NANO
Volume 9, Issue 1, Pages 16-30Publisher
AMER CHEMICAL SOC
DOI: 10.1021/nn5062029
Keywords
cancer immunotherapy; tumor immune surveillance; tumor immune evasion; tumor immunoediting; tumor-associated antigens; danger-associated molecular patterns; T-lymphocytes; lymphocyte co-stimulators; vaccines; nanoparticles; targeted delivery; environment-responsive nanoparticles
Categories
Funding
- Canadian Institutes of Health Research (CIHR)
- Natural Sciences and Engineering Research Council of Canada (NSERC)
- Diabetes Research Foundation (DRF)
- Juvenile Diabetes Research Foundation (JDRF)
- Canadian Diabetes Association (CDA)
- Multiple Sclerosis Society of Canada (MSSC)
- Brawn Family Foundation
- Sarda Farriol Research Programme
- European Community's Seventh Framework Programme (EC FP7) [229673]
- Eyes' High/Alberta Innovates-Technology Futures postdoctoral fellowship
- AXA Research Fund
- endMS network
- Alberta Heritage Foundation of Medical Research (AHFMR)
- Diabetes Association (Foothills)
- CDA
Ask authors/readers for more resources
The design of nanovaccines capable of triggering effective antitumor immunity requires an understanding of how the immune system senses and responds to threats, including pathogens and tumors. Equally important is an understanding of the mechanisms employed by tumor cells to evade immunity and an appreciation of the deleterious effects that antitumor immune responses can have on tumor growth, such as by skewing tumor cell composition toward immunologically silent tumor cell variants. The immune system and tumors engage in a tug-of-war driven by competition where promoting antitumor immunity or tumor cell death alone may be therapeutically insufficient. Nanotechnology affords a unique opportunity to develop therapeutic compounds than can simultaneously tackle both aspects, favoring tumor eradication. Here, we review the current status of nanoparticle-based immunotherapeutic strategies for the treatment of cancer, ranging from antigen/adjuvant delivery vehicles (to professional antigen-presenting cell types of the immune system) to direct tumor antigen-specific T-lymphocyte-targeting compounds and their combinations thereof.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available